San Francisco—Hims & Hers Health, Inc. (NYSE:HIMS) Chief Financial Officer Okupe Oluyemi recently made significant transactions involving the company's Class A Common Stock. According to a recent SEC filing, Oluyemi sold shares totaling approximately $5.48 million on October 14, 2024. The shares were sold at prices ranging from $19.9494 to $21.0699 per share.
Additionally, Oluyemi executed stock option exercises, acquiring shares at prices between $5.01 and $11.53. These transactions were conducted under a Rule 10b5-1 trading plan adopted earlier this year on May 31, 2024. Following these transactions, Oluyemi holds 145,763 shares directly.
In other recent news, Hims & Hers Health, Inc. reported a remarkable 52% year-over-year revenue increase in Q2 2024, reaching $316 million, and an adjusted EBITDA of $39 million. The company also expanded its market reach through the acquisition of MedisourceRx, issuing 976,341 Class A common shares to Nivagen Pharmaceuticals, Inc. In the wake of these developments, BofA Securities raised its price target for Hims & Hers from $20.00 to $23.00, maintaining a Buy rating. This adjustment followed the FDA's announcement to reassess the availability of tirzepatide, a drug previously on the agency's shortage list. Truist Securities and Citi maintained their hold and neutral ratings, respectively, while Canaccord Genuity (TSX:CF) sustained its Buy rating, citing the potential of the company's compounded GLP-1 medications amid rising obesity trends. These are recent developments that continue to shape the trajectory of Hims & Hers.
InvestingPro Insights
The recent stock transactions by Hims & Hers Health's CFO Okupe Oluyemi align with several key insights from InvestingPro. The company's stock has shown remarkable performance, with InvestingPro data indicating a 263.06% price total return over the past year and a 79.67% return in the last six months. This strong momentum is reflected in an InvestingPro Tip noting a "significant return over the last week," with the stock up 21.73% in just seven days.
Despite the impressive stock performance, investors should be aware that Hims & Hers is currently trading at a high valuation. The company's P/E ratio stands at 268.24, and an InvestingPro Tip cautions that it is "trading at a high earnings multiple." This elevated valuation comes as the company experiences robust growth, with revenue increasing by 50.15% in the last twelve months to $1.07 billion.
Interestingly, while the CFO has sold shares, another InvestingPro Tip reveals that "management has been aggressively buying back shares," suggesting confidence in the company's future prospects. For investors seeking a more comprehensive analysis, InvestingPro offers 16 additional tips for Hims & Hers Health, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.